NASDAQ: EIKNEikon Therapeutics Inc Stock
$10.64-1.11 (-9.45%)
Updated May 19, 2026
EIKN Price
$10.64
Fair Value Price
-$2.82
Market Cap
$576.04M
52 Week Low
$7.90
52 Week High
$16.50
P/E
N/A
P/B
1.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.55
Operating Cash Flow
N/A
Beta
2.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EIKN Overview
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004, to address brain metastases and primary brain malignancies; EIK1005 a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006. The company was incorporated in 2019 and is based in Millbrae, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EIKN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EIKN
Ranked#333 of 462
Ranked#333 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $237.45 | A | |
| $48.67 | A | |
| $1.90 | A |
Be the first to know about important EIKN news, forecast changes, insider trades & much more!
EIKN News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EIKN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EIKN ($10.64) is overvalued by 477.93% relative to our estimate of its Fair Value price of -$2.82 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EIKN ($10.64) is not significantly undervalued (477.93%) relative to our estimate of its Fair Value price of -$2.82 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EIKN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more EIKN due diligence checks available for Premium users.
Valuation
EIKN fair value
Fair Value of EIKN stock based on Discounted Cash Flow (DCF)
Price
$10.64
Fair Value
-$2.82
Undervalued by
477.93%
EIKN ($10.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EIKN ($10.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EIKN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.05x
Industry
4.72x
EIKN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EIKN's financial health
Profit margin
Revenue
$0.0
Net Income
-$83.0M
Profit Margin
0%
Assets to liabilities
Assets
$850.8M
Liabilities
$300.2M
Debt to equity
0.55
EIKN's short-term assets ($529.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EIKN's short-term assets ($529.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EIKN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$89.8M
Investing
-$203.2M
Financing
$349.3M
EIKN vs Biotech Stocks
Eikon Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.